Answers are grounded in this paper and cite their sources.
Previous research has demonstrated that ergot alkaloids (EA) decrease circulating serotonin, and 5-hydroxytryptophan (5-HTP) supplementation increases circulating serotonin. It remains unclear if changes in serotonin bioavailability and/or feed intake are associated with alterations in hypothalamic function. The objective was to evaluate the effects of EA and 5-HTP supplementation on serotonin bioavailability, feed intake, and the transcriptomic profile of the hypothalamus in beef cattle. AnguśHolstein steers [n = 24; body weight (BW)=427±101 kg] were ruminally-dosed with non-toxic or toxic endophyte-infected tall fescue seed to provide 0 or 15 mg ergovaline/kg of BW. Additionally, steers were ruminally dosed with 0 or 3 mg 5-HTP/kg of BW. Therefore, the four treatments were: control, 5-HTP, EA, EA + 5-HTP. Steers were housed indoors in individual pens, exposed to cyclical temperatures mimicking summer conditions (21 °C–32 °C), and limit-fed alfalfa cubes to supply 1.5 times the net energy required for maintenance. Feed intake and feeding behavior were measured daily. Blood samples were collected in 7-d intervals and analyzed for serotonin concentration using high-performance liquid chromatography. On day 16, the hypothalamus was collected for RNA sequencing after slaughter. There were four unique serotonergic phenotypes (P = 0.05): 5-HTP increased serum serotonin relative to control; EA decreased serum serotonin relative to control, and the combination (EA + 5-HTP) decreased serum serotonin compared to all other treatments. Ergot alkaloid consumption decreased dry matter intake (P = 0.04), meal duration (P = 0.03), and meal size (P < 0.01). 5-hydroxytryptophan supplementation did not influence (P > 0.05) meal duration, meal size, or dry matter intake versus no 5-HTP supplementation. 5-hydroxytryptophan, EA, or their combination (EA + 5-HTP) downregulated (P < 0.01) genes associated with the serotonergic synapse. 5-hydroxytryptophan, EA, or their combination (EA + 5HTP) downregulated (3.5-fold, 5.5-fold, 3.9-fold, respectively; P < 0.01) mRNA expression of tryptophan hydroxylase 2 (TPH2), the rate-limiting enzyme catalyzing the conversion of 5-HTP to serotonin in the hypothalamus. 5-hydroxytryptophan, EA, and their combination (EA + 5-HTP) downregulated (3.3-fold, 3.8-fold, and 4.9-fold, respectively; P < 0.01) mRNA expression of the serotonin reuptake transporter (SLC6A4). 5-hydroxytryptophan, EA, or their combination (EA + 5-HTP) downregulated (3.2-fold, 3.3-fold, 5-fold, respectively; P < 0.01) mRNA expression of FEV, a transcription factor essential for differentiation, growth, and development of hypothalamic serotonergic neurons. Ergot alkaloids and 5-HTP downregulated (P < 0.01) mRNA expression of serotonergic receptors, including HTR1A and HTR1B. Ergot alkaloids downregulated (P < 0.01) several transcripts (NPY, CCK, GLP1R, and GHSR) associated with neuroactive ligand-receptor interactions. 5-hydroxytryptophan upregulated (P < 0.01) several transcripts (VIP, NMS, and POMC) associated with neuroactive ligand-receptor interactions. Transcripts associated with hypothalamic serotonin synthesis, transport, signaling, and reuptake were downregulated by EA and 5-HTP supplementation. Transcripts associated with hypothalamic neuroactive ligand-receptor interactions were differentially regulated by EA and 5-HTP. These findings demonstrate that EA and 5-HTP modulate hypothalamic serotonergic signaling and appetite-related pathways, suggesting associations with the regulation of feed intake and systemic serotonin bioavailability in cattle.
No takes yet. Share an insight, caveat, or question.
Byrd et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: